Pharmacological Activation of NRF2 by Omaveloxolone Upregulates NRF2-Target Proteins in SMA Type I Human Fibroblasts

This study demonstrates that the pharmacological NRF2 activator Omaveloxolone upregulates NRF2-target proteins and modestly increases SMN protein levels in Spinal Muscular Atrophy type I fibroblasts, which exhibit diminished basal NRF2 pathway output compared to controls.

The Gist

The Big Picture: A City in Trouble

Imagine the human body as a bustling city. In Spinal Muscular Atrophy (SMA), a specific type of "construction worker" called the SMN protein is missing or broken. Usually, this worker helps build and maintain the city's power lines and communication networks (specifically in nerve cells). Without enough SMN, the city starts to crumble, leading to muscle weakness and paralysis.

For a long time, scientists thought this problem only happened in the "power lines" (motor neurons). But this new study suggests the problem is actually happening all over the city, even in the "backup generators" (fibroblasts, which are simple cells we can grow in a lab).

The Problem: The City's Fire Department is Asleep

Inside every cell, there is a safety system called NRF2. Think of NRF2 as the City Fire Department. Its job is to detect smoke (oxidative stress) and immediately send out fire trucks (protective proteins) to put out fires and keep the city safe.

The researchers discovered that in SMA patients, this Fire Department is asleep.

• The Evidence: When they looked at cells from SMA patients, they found very few fire trucks (proteins like NQO1 and xCT) on the streets. The cells were vulnerable and lacked the tools to handle stress.
• The Extra Issue: They also noticed that the city's power plant (mitochondria) was running poorly. A key manager of the power plant, called PGC1α, was also missing in low numbers.

The Experiment: Waking Up the Fire Department

The scientists wanted to see if they could use a "wake-up call" to get the Fire Department working again. They tested several different "alarms" (drugs) on cells from healthy people and people with SMA.

1. The Failed Alarms: They tried some common alarms (drugs like Sulforaphane and NAC). These didn't work well; in fact, some were too harsh and actually hurt the cells.
2. The Magic Key (Omaveloxolone): They then tried a specific drug called Omaveloxolone (OMAV). This drug is already approved for a different disease (Friedreich's ataxia), so we know it's generally safe.
   • The Result: When they used OMAV, it was like hitting the emergency siren. The Fire Department woke up! The cells immediately started producing more fire trucks (NQO1 and xCT).
   • The Bonus: Not only did the Fire Department wake up, but the power plant manager (PGC1α) also showed up in the SMA cells, and surprisingly, the missing construction worker (SMN protein) started appearing in small numbers again.

The Analogy: The "Home Renovation"

Think of the SMA cell as a house that is falling apart because the main contractor (SMN) is missing.

• Before the drug: The house has no security system (NRF2 is low), the lights are flickering (mitochondria are weak), and the roof is leaking.
• After the drug (OMAV): The drug acts like a smart home upgrade.
  • It installs a new security system (boosts NRF2 targets) to protect the house from damage.
  • It fixes the electrical wiring (boosts PGC1α).
  • And, in a surprising twist, it seems to help the missing contractor (SMN) show up a little bit, perhaps because the house is now a safer, more stable place for them to work.

Why This Matters

This study is important for three reasons:

1. It confirms the problem is widespread: Even simple cells in SMA patients have a broken safety system, not just the nerve cells.
2. It offers a new treatment path: The drug Omaveloxolone successfully woke up the body's natural defense systems in human cells.
3. It hints at a double benefit: The drug didn't just protect the cells; it actually helped increase the levels of the missing SMN protein in SMA cells, which is the root cause of the disease.

The Bottom Line

The researchers found that SMA cells are like a city without a fire department. By using a drug called Omaveloxolone, they were able to wake up the fire department, fix the power plant, and even bring back a few of the missing construction workers. While more research is needed to understand exactly how the drug brings back the construction workers, this is a very promising step toward new ways to treat SMA.

Technical Summary

1. Problem Statement

Spinal Muscular Atrophy (SMA) is a neuromuscular disorder caused by the loss of the SMN1 gene, leading to insufficient levels of Survival Motor Neuron (SMN) protein. While traditionally viewed as a motor neuron disease, recent evidence suggests SMA is a multisystem disorder involving metabolic dysfunction and redox imbalance in peripheral tissues. Previous studies in SMA mouse models indicated dysregulation of the NRF2-KEAP1 signaling pathway, a central cytoprotective axis responsible for maintaining cellular redox homeostasis and adapting to oxidative stress. However, it remained unclear whether this dysregulation exists in human SMA patient-derived cells and whether pharmacological activation of NRF2 could offer therapeutic benefits beyond motor neuron rescue.

2. Methodology

The study utilized human fibroblasts derived from:

• Control subjects: 2 copies of SMN1, 1–2 copies of SMN2.
• SMA Type I patients: 0 copies of SMN1, 2 copies of SMN2.

Experimental Workflow:

1. Viability Screening: Cells were treated with various NRF2-modulating compounds:
   • Sulforaphane (SFN) and Dimethyl Fumarate (DMF): Known NRF2 activators.
   • N-acetylcysteine (NAC): An antioxidant precursor.
   • Omaveloxolone (OMAV): A potent, FDA-approved pharmacological NRF2 activator (approved for Friedreich's ataxia).
   • Viability was assessed via MTT assay at 24, 48, 72, and 96 hours.
2. Protein Expression Analysis: Based on viability results, cells were treated with OMAV (100 nM or 200 nM) for 48 hours (daily refreshment).
3. Western Blotting: Membranes were probed for:
   • NRF2 Targets: NQO1 (NAD(P)H quinone dehydrogenase 1) and xCT (SLC7A11, cystine-glutamate antiporter).
   • Metabolic Regulator: PGC1α (Peroxisome proliferator-activated receptor gamma coactivator-1 alpha).
   • Disease Protein: SMN.
   • Total protein staining was used for normalization.
4. Statistical Analysis: Data were analyzed using one-way and two-way ANOVA with appropriate post-hoc tests (Dunnett's or Šídák's).

3. Key Contributions

• Validation of Redox Dysregulation in Human Cells: The study confirms that the NRF2 pathway output is diminished in human SMA Type I fibroblasts, not just in mouse models.
• Identification of OMAV as a Candidate: The research identifies Omaveloxolone as a viable pharmacological agent that can activate NRF2 signaling in human SMA cells, whereas other common activators (SFN, DMF) showed toxicity at effective doses.
• Discovery of Secondary Effects: The study reports a novel, selective increase in SMN protein abundance and PGC1α levels in SMA cells following NRF2 activation, suggesting a potential feedback loop between redox homeostasis and SMN stability.

4. Key Results

• Basal Deficits in SMA Fibroblasts:
  • Untreated SMA fibroblasts exhibited significantly reduced basal levels of NRF2 target proteins (NQO1 and xCT) compared to controls.
  • SMA fibroblasts also showed decreased levels of PGC1α, a key regulator of mitochondrial biogenesis, linking SMN deficiency to metabolic perturbations.
• Compound Screening (Viability):
  • SFN and DMF: Higher concentrations reduced cell viability in both control and SMA cells, indicating a narrow therapeutic window or toxicity.
  • NAC: Showed no significant effect on cell viability.
  • OMAV: Treatment with 100 nM or 200 nM OMAV increased cell viability in both control and SMA fibroblasts and was well-tolerated.
• Protein Induction by OMAV:
  • NRF2 Targets: OMAV successfully upregulated NQO1 and xCT in both control and SMA fibroblasts, confirming pathway activation.
  • SMA-Specific Effects:
    • In Control cells, OMAV did not alter SMN or PGC1α levels.
    • In SMA cells, OMAV (specifically at 100 nM) induced a modest but significant increase in SMN protein abundance and PGC1α levels.
• Mechanistic Insight: The increase in SMN and PGC1α was observed only in the SMN-deficient context, suggesting that restoring redox balance via NRF2 activation may create a cellular environment favorable for SMN protein accumulation or stability.

5. Significance and Implications

• Multisystem Nature of SMA: The findings reinforce the concept that SMA involves systemic redox and metabolic dysfunction, extending beyond the neuromuscular compartment.
• Therapeutic Potential of NRF2 Activation: Omaveloxolone represents a promising therapeutic strategy for SMA. By enhancing cytoprotective signaling, it not only improves cell viability but also upregulates mitochondrial regulators (PGC1α) and potentially stabilizes the disease-causing protein (SMN).
• Translational Relevance: Since OMAV is already approved for Friedreich's ataxia, these results suggest a potential path for drug repurposing for SMA treatment, potentially as an adjunct to existing SMN-restoring therapies.
• Future Directions: The study highlights the need for further mechanistic research to elucidate how NRF2 activation influences SMN protein stability and turnover, which could lead to optimized combination therapies.

Conclusion:
This study demonstrates that SMA Type I fibroblasts suffer from diminished NRF2 pathway output. Pharmacological activation of NRF2 by Omaveloxolone rescues this deficit, upregulates cytoprotective proteins, improves cell viability, and uniquely increases SMN and PGC1α levels in SMA cells, offering a novel therapeutic avenue for addressing the multisystem pathology of SMA.